Biomea Fusion Inc (BMEA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.03+6.28%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BMEA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BMEA — debt issuance
Dated 2025-10-07
Entry into a Material Definitive Agreement. On October 6, 2025, Biomea Fusion, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, as representative of the several underwriters named therein (the “Underwriters”) relating to an underwritten offering (the “Offering”) of (i) 11,195,121 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), (ii) in lieu of Common Stock to certain investors,…
Why it matters: The 26-week data for T2D diabetes treatment will show if icovamenib works well. This could change how the market sees it.
Watch forA report showing positive 26-week data results for T2D diabetes.
Also watch forNegative or inconclusive results from the 26-week data.
Why it matters: Starting this trial shows Biomea's plan to grow icovamenib's uses. It may help investor trust.
Supportive ifThe trial has started. Patient enrollment is confirmed at academic centers.
Worry ifNo announcement of trial initiation by the end of 2026.
Why it matters: Updates on the COVALENT-112 trial show progress for icovamenib. Good results could help investors.
Supportive ifA press release confirms good interim results from the COVALENT-112 trial.
Worry ifNo updates or negative results from the trial.
Why it matters: This data will show how well BMF-650 works for weight loss. Positive results could boost investor confidence.
Supportive ifInitial 28-day weight reduction data from the Phase I GLP-131 (BMF-650) trial shows at least a 5% reduction.
Worry ifWeight reduction data shows no significant change or an increase in weight.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$241 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $768 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,415 loss on $10,000 · 64.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: These results will show how well icovamenib works for Type 2 diabetes. Good data may attract more interest in the stock.
Supportive ifData from COVALENT-211 and COVALENT-212 shows better control of blood sugar.
Worry ifData shows no clear change in blood sugar control compared to the placebo.
Why it matters: Starting this trial shows commitment to expanding icovamenib's use. It could lead to new data that supports the drug's potential.
Supportive ifThe Phase II trial in recently diagnosed T1D patients starts as planned in H2 2026.
Worry ifThe trial is delayed or canceled. This suggests there may be problems with the program.
Why it matters: Updates on cash runway will show if the company can fund its trials. A strong runway supports ongoing operations.
Watch forCash runway lasts until Q2 2027. This shows the company is financially stable.
Also watch forCash runway projected to end before Q2 2027, raising concerns about funding.